Answers are grounded in this paper and cite their sources.
The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clinical use.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: